Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance

Area of Science:

• Oncology
• Nanomedicine
• Biochemistry

Background:

• Tumor drug resistance is a major challenge in cancer chemotherapy.
• Tumor cells employ various mechanisms to resist anticancer drug accumulation.
• Novel therapeutic strategies are needed to overcome chemoresistance.

Purpose of the Study:

• To investigate the combined efficacy of doxorubicin and methylene blue photodynamic therapy (PDT) in a drug-resistant mouse tumor model.
• To evaluate the use of surfactant-polymer hybrid nanoparticles for synchronized drug delivery.
• To assess the impact of this combination therapy on tumor growth and animal survival.

Main Methods:

• Formulation of surfactant-polymer hybrid nanoparticles using Aerosol-OT and sodium alginate for co-delivery of doxorubicin and methylene blue.
• Utilized a drug-resistant Balb/c mouse model with syngeneic JC tumors (mammary adenocarcinoma).
• Administered nanoparticle-mediated combination therapy and assessed tumor growth, animal survival, drug accumulation, proliferation, and apoptosis.

Main Results:

• Nanoparticle-mediated combination therapy significantly inhibited tumor growth and improved survival rates in the drug-resistant model.
• Enhanced tumor accumulation of both doxorubicin and methylene blue was observed.
• Significant inhibition of tumor cell proliferation and increased induction of apoptosis were noted.

Conclusions:

• Nanoparticle-mediated combination of doxorubicin chemotherapy and methylene blue photodynamic therapy demonstrates significant therapeutic potential against drug-resistant tumors.
• Synchronized delivery via hybrid nanoparticles enhances drug efficacy and overcomes resistance mechanisms.
• This approach offers a promising strategy for improving outcomes in chemoresistant cancers.